LGND logo

LGND

Ligand Pharmaceuticals Incorporated

$161.71
+$1.75(+1.09%)
66
Overall
--
Value
72
Tech
60
Quality
Market Cap
$3.13B
Volume
147.03K
52W Range
$93.58 - $163.34
Target Price
$168.14
Order:

Income Statement

MetricTrendChart
2015
Dec
2016
Dec
2017
Dec
2018
Dec
2019
Dec
2020
Dec
2021
Dec
2022
Dec
2023
Dec
2024
Dec
REVENUE
Total Revenue
$71.9M$109.0M$141.1M$251.5M$120.3M$186.4M$241.5M$196.2M$131.3M$167.1M
Total Revenue
$27.7M$22.5M$141.1M$251.5M$120.3M$163.6M$241.5M$196.2M$131.3M$167.1M
COST OF GOODS SOLD
Cost of Revenue
$-5.8M$-5.6M$-5.4M$6.3M$11.3M$30.4M$62.2M$52.8M$10.5M$11.1M
GROSS PROFIT
Gross Profit
$66.1M$103.4M$135.7M$245.1M$108.9M$133.1M$179.4M$143.4M$120.8M$156.1M
OPERATING EXPENSES
Operating Expenses
$-44.6M$-65.1M$-73.0M$-87.7M$126.0M$177.7M$137.7M$140.4M$121.5M$189.7M
Research & Development
$11.0M$21.2M$26.9M$27.9M$55.9M$59.4M$32.1M$36.1M$24.5M$21.4M
Research Expense
$11.0M$21.2M$26.9M$27.9M$55.9M$59.4M$32.1M$36.1M$24.5M$21.4M
Selling, General & Administrative
$24.4M$27.7M$28.7M$37.7M$41.9M$64.4M$46.8M$104.3M$52.8M$111.6M
Selling & Marketing Expenses
------------$47.2M$34.2M--$33.0M
General & Administrative Expenses
$24.4M$27.7M$28.7M$37.7M$41.9M$64.4M$46.8M$70.1M$52.8M$78.7M
Salaries & Wages
$-12.5M$-18.9M$-24.9M$-20.8M$24.5M$30.7M$29.3M$50.9M$33.7M--
Depreciation & Amortization
$2.4M$10.6M$12.1M$15.8M$1.5M$1.8M$34.2M$3.8M$2.9M$2.3M
Depreciation & Amortization
$2.4M$10.6M$12.1M$15.8M$1.5M$1.8M$34.2M$3.8M----
Amortization
$2.4M$10.6M$12.1M$15.8M$210.4M$595.3M$34.2M$139.9M$137.0M$138.2M
Other Operating Expenses
$-154.0K$-70.0K$-1.1M$-1.2M$-543.0K$-3.9M$-37.6M$-58.0K----
OPERATING INCOME
Operating income
$28.3M$43.9M$68.1M$163.7M$807.1M$25.8M$103.9M$3.0M$11.9M$-22.6M
EBITDA
$48.2M$30.5M$93.9M$274.8M$895.8M$70.2M$142.8M$89.2M$100.8M$41.3M
NON-OPERATING ITEMS
Interest Expense (Non-Operating)
----$13.5M$48.3M$35.7M$27.4M$19.6M$1.8M$656.0K$3.0M
Intinc
------$14.0M$28.4M$8.1M$886.0K$2.0M$7.7M$8.1M
Net Non-Operating Interest Income/Expense
----$-13.5M$-34.3M$-7.3M$-19.3M$-18.7M$247.0K$7.1M$5.0M
Gain on Sale of Securities
$28.2M--$12.0K$50.2M$1.0M$-16.9M$-5.3M$28.5M$46.4M$60.0M
Other Income/Expense
$-19.8M$23.7M$-2.6M$-43.9M$-809.7M$17.0M$12.9M$32.7M$-46.8M$25.5M
Other Special Charges
$1.8M$2.7M$2.6M$-6.3M$808.6M$-108.0K$-7.7M$4.2M$-1.7M$-54.9M
SPECIAL ITEMS
Restructring And Mn A Income
$1.0M$1.0M----------------
Special Income Charges
$-1.0M$-1.0M----$-16.9M$-23.4M$37.6M------
Impairment of Capital Assets
--------$16.9M----------
PRE-TAX INCOME
EBIT
$35.3M$8.0M$70.7M$221.6M$832.4M$19.1M$91.8M$37.8M$64.3M$5.6M
Pre-Tax Income
$35.3M$8.0M$57.2M$173.3M$796.6M$-10.5M$72.2M$36.0M$63.7M$2.5M
INCOME TAX
Tax Provision
$-192.1M$10.3M$44.7M$30.0M$167.3M$-5.3M$-4.1M$41.2M$9.8M$6.5M
NET INCOME
Net Income
$229.8M$-3.3M$12.6M$143.3M$629.3M$-3.0M$57.1M$-33.4M$52.2M$-4.0M
Net Income (Continuing Operations)
$229.8M$-3.3M$12.6M$143.3M$629.3M$-3.0M$57.1M$-5.2M$53.8M$-4.0M
Net Income (Discontinued Operations)
$229.8M$-3.3M$12.6M$143.3M$629.3M$-3.0M$57.1M$-33.4M$52.2M$-4.0M
Net Income (Common Stockholders)
$229.8M$-3.3M$12.6M$143.3M$629.3M$-3.0M$57.1M$-33.4M$52.2M$-31.1M
TOTALS
Total Expenses
$-50.4M$-70.7M$-78.4M$-81.4M$137.3M$208.1M$199.9M$193.2M$132.0M$200.8M
SHARE & EPS DATA
Average Shares Outstanding
$31.7M$33.4M$33.7M$33.9M$30.4M$25.9M$26.7M$16.9M$17.3M$18.3M
Average Shares Outstanding (Diluted)
$34.0M$33.4M$37.6M$38.6M$31.7M$25.9M$27.6M$16.9M$17.8M$18.3M
Shares Outstanding
$33.3M$33.5M$34.0M$32.8M$26.5M$26.6M$27.0M$17.1M$17.7M$19.3M
Basic EPS
--------$20.67$-0.11$2.15$-1.98$3.02$-0.22
Basic EPS (Continuing Operations)
$8.11$-0.07$0.37$4.22$20.67$-0.11$2.15$-0.31$3.11$-0.22
Diluted EPS
--------$19.87$-0.11$2.06$-1.98$2.94$-0.22
Diluted EPS (Continuing Operations)
$7.56$-0.07$0.33$3.72$19.87$-0.11$2.06$-0.31$3.03$-0.22
OTHER METRICS
Basic Discontinuous Operations
--$0.02----------$-1.67$-0.10--
Commission Expenses
------------$47.2M$34.2M----
Diluted Discontinuous Operations
--$0.02----------$-1.67$-0.09--
Earnings from equity interest
$-5.1M$-23.1M$-2.0M--------------
Earnings From Equity Interest Net Of Tax
$-5.1M$-23.1M$-2.0M--------------
Excise Taxes
--------$16.9M------$33.7M--
Gain On Sale Of Business
--$1.1M------------$2.1M--
Gains Loss On Disposal Of Discontinued Operations
--$731.0K----------------
Minority Interests
$2.4M------$767.2M----------
Net Income Discontinuous Operations
--$731.0K--------$-19.2M$-28.1M$-1.7M--
Net Income Extraordinary
--$-1.6M$12.6M--------------
Net Operating Interest Income Expense
$-11.8M$-12.2M$-11.4M--------------
Other Gain Loss From Disposition Of Discontinued Operations
------------$-19.2M$-28.1M----
Other Gand A
$24.4M$27.7M$28.7M$37.7M$41.9M$64.4M$46.8M$70.1M$52.8M$78.7M
Other Impairment Of Capital Assets
------------------$30.6M
Other Write Off
--------------$300.0K----
Rent And Landing Fees
$24.4M$27.7M$28.7M$37.7M------------
Write Off
----------$23.4M--------
Othspecchg
------------$-37.6M------
Restruct
$1.0M$1.0M----------------

Financial data is updated quarterly and may not reflect the most recent earnings.

ABCD
1SymbolPriceChangeVol
2LGND$161.71+1.1%147.03K
3
4
5
6

Get Ligand Pharmaceuticals Incorporated Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.